The University of Chicago Header Logo

Connection

Mark J. Ratain to Pharmacogenetics

Back to Details
This is a "connection" page, showing publications Mark J. Ratain has written about Pharmacogenetics.
Mark J. Ratain
Connection Strength
9.923
Pharmacogenetics
  1. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.441
  2. The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone. Clin Pharmacol Ther. 2016 Apr; 99(4):401-4.
    View in: PubMed
    Score: 0.402
  3. Meaningful use of pharmacogenetics. Clin Pharmacol Ther. 2014 Dec; 96(6):650-2.
    View in: PubMed
    Score: 0.370
  4. Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project". Am J Med Genet C Semin Med Genet. 2014 Mar; 166C(1):68-75.
    View in: PubMed
    Score: 0.352
  5. Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science. Pharmacogenomics. 2013 Sep; 14(12):1383-7.
    View in: PubMed
    Score: 0.339
  6. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013 Jan; 14(1):23-34.
    View in: PubMed
    Score: 0.322
  7. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther. 2012 Oct; 92(4):446-9.
    View in: PubMed
    Score: 0.316
  8. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol. 2012 Apr; 6(2):251-9.
    View in: PubMed
    Score: 0.303
  9. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb; 59(1):42-55.
    View in: PubMed
    Score: 0.245
  10. Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther. 2008 Sep; 84(3):393-402.
    View in: PubMed
    Score: 0.234
  11. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
    View in: PubMed
    Score: 0.232
  12. Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. Pharmacogenomics. 2007 May; 8(5):519.
    View in: PubMed
    Score: 0.219
  13. Personalized medicine: building the GPS to take us there. Clin Pharmacol Ther. 2007 Mar; 81(3):321-2.
    View in: PubMed
    Score: 0.216
  14. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics. 2006 Dec; 7(8):1211-21.
    View in: PubMed
    Score: 0.212
  15. The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol. 2006 Jul; 62(1):35-46.
    View in: PubMed
    Score: 0.206
  16. Irinogenetics: what is the right star? J Clin Oncol. 2006 May 20; 24(15):2221-4.
    View in: PubMed
    Score: 0.204
  17. EGFR pharmacogenomics: the story continues to mutate and evolve. Am J Pharmacogenomics. 2005; 5(2):137-9.
    View in: PubMed
    Score: 0.186
  18. Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance). Pharmacogenomics J. 2024 Mar 04; 24(2):6.
    View in: PubMed
    Score: 0.176
  19. Pharmacogenomics: road to anticancer therapeutics nirvana? Oncogene. 2003 Sep 29; 22(42):6621-8.
    View in: PubMed
    Score: 0.170
  20. UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics. 2003 Aug; 13(8):517-23.
    View in: PubMed
    Score: 0.169
  21. Implementation of pharmacogenomics into inpatient general medicine. Pharmacogenet Genomics. 2023 02 01; 33(2):19-23.
    View in: PubMed
    Score: 0.161
  22. Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial. Anesth Analg. 2022 11 01; 135(5):929-940.
    View in: PubMed
    Score: 0.153
  23. Pharmacogenetics in cancer treatment. Annu Rev Med. 2003; 54:437-52.
    View in: PubMed
    Score: 0.150
  24. Validation of a Large Custom-Designed Pharmacogenomics Panel on an Array Genotyping Platform. J Appl Lab Med. 2021 11 01; 6(6):1505-1516.
    View in: PubMed
    Score: 0.149
  25. Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application. Pharmacogenomics J. 2021 12; 21(6):691-711.
    View in: PubMed
    Score: 0.147
  26. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos. 2001 Apr; 29(4 Pt 2):596-600.
    View in: PubMed
    Score: 0.143
  27. Patient insights on features of an effective pharmacogenomics patient portal. Pharmacogenet Genomics. 2020 12; 30(9):191-200.
    View in: PubMed
    Score: 0.140
  28. Pharmacogenetics: a tool for individualizing antineoplastic therapy. Clin Pharmacokinet. 2000 Nov; 39(5):315-25.
    View in: PubMed
    Score: 0.139
  29. Pharmacogenomic-Based Decision Support to Predict Adherence to Medications. Clin Pharmacol Ther. 2020 08; 108(2):368-376.
    View in: PubMed
    Score: 0.135
  30. Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation. Pharmacogenomics J. 2020 02; 20(1):126-135.
    View in: PubMed
    Score: 0.129
  31. Pharmacogenomic considerations for medications in the perioperative setting. Pharmacogenomics. 2019 07; 20(11):813-827.
    View in: PubMed
    Score: 0.127
  32. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J. 2019 12; 19(6):528-537.
    View in: PubMed
    Score: 0.124
  33. Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study. Pharmacogenet Genomics. 2019 02; 29(2):31-38.
    View in: PubMed
    Score: 0.123
  34. Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing. Pharmacogenet Genomics. 2019 02; 29(2):23-30.
    View in: PubMed
    Score: 0.123
  35. Essential Characteristics of Pharmacogenomics Study Publications. Clin Pharmacol Ther. 2019 01; 105(1):86-91.
    View in: PubMed
    Score: 0.123
  36. A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). Clin Pharmacol Ther. 2019 03; 105(3):738-745.
    View in: PubMed
    Score: 0.121
  37. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065.
    View in: PubMed
    Score: 0.117
  38. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018 05; 103(5):770-777.
    View in: PubMed
    Score: 0.115
  39. Simplifying the use of pharmacogenomics in clinical practice: Building the genomic prescribing system. J Biomed Inform. 2017 Nov; 75:110-121.
    View in: PubMed
    Score: 0.112
  40. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems. Clin Pharmacol Ther. 2017 Sep; 102(3):502-510.
    View in: PubMed
    Score: 0.110
  41. Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program. Clin Pharmacol Ther. 2017 07; 102(1):106-114.
    View in: PubMed
    Score: 0.109
  42. Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Nat Rev Drug Discov. 2017 Jan; 16(1):1.
    View in: PubMed
    Score: 0.106
  43. Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration. Clin Pharmacol Ther. 2016 Nov; 100(5):423-426.
    View in: PubMed
    Score: 0.104
  44. Disease-drug database for pharmacogenomic-based prescribing. Clin Pharmacol Ther. 2016 08; 100(2):179-90.
    View in: PubMed
    Score: 0.103
  45. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016 04; 99(4):363-9.
    View in: PubMed
    Score: 0.099
  46. Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). J Natl Cancer Inst. 2015 Oct; 107(10).
    View in: PubMed
    Score: 0.096
  47. Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clin Proc. 2015 Jun; 90(6):716-29.
    View in: PubMed
    Score: 0.096
  48. Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med. 2012 Sep 26; 4(153):153ps18.
    View in: PubMed
    Score: 0.079
  49. Pharmacogenomics: will the promise be fulfilled? Nat Rev Genet. 2011 01; 12(1):69-73.
    View in: PubMed
    Score: 0.070
  50. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
    View in: PubMed
    Score: 0.069
  51. A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenet Genomics. 2010 Oct; 20(10):638-41.
    View in: PubMed
    Score: 0.069
  52. Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov. 2008 07; 7(7):568-74.
    View in: PubMed
    Score: 0.059
  53. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Pharmacotherapy. 2008 Jun; 28(6):755-68.
    View in: PubMed
    Score: 0.059
  54. Interpreting P values in pharmacogenetic studies: a call for process and perspective. J Clin Oncol. 2007 Oct 10; 25(29):4513-5.
    View in: PubMed
    Score: 0.056
  55. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007 Mar; 81(3):328-45.
    View in: PubMed
    Score: 0.054
  56. Pharmacogenomics: challenges and opportunities. Ann Intern Med. 2006 Nov 21; 145(10):749-57.
    View in: PubMed
    Score: 0.053
  57. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci. 2006 Aug; 27(8):432-7.
    View in: PubMed
    Score: 0.052
  58. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3612s-6s.
    View in: PubMed
    Score: 0.051
  59. Interpreting disparate responses to cancer therapy: the role of human population genetics. J Clin Oncol. 2006 May 10; 24(14):2151-7.
    View in: PubMed
    Score: 0.051
  60. From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin Cancer Res. 2006 Mar 15; 12(6):1658-60.
    View in: PubMed
    Score: 0.051
  61. Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes. Pharmacogenet Genomics. 2006 Feb; 16(2):79-86.
    View in: PubMed
    Score: 0.050
  62. Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care. Pharmacogenet Genomics. 2022 04 01; 32(3):79-86.
    View in: PubMed
    Score: 0.038
  63. Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer. 2002 Mar; 38(5):639-44.
    View in: PubMed
    Score: 0.038
  64. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer. 2022 Apr 15; 128(8):1649-1657.
    View in: PubMed
    Score: 0.038
  65. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients. Oncologist. 2021 11; 26(11):e2042-e2052.
    View in: PubMed
    Score: 0.037
  66. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol. 2001 Apr 01; 19(7):2084-90.
    View in: PubMed
    Score: 0.036
  67. Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis. Clin Exp Rheumatol. 2021 Nov-Dec; 39(6):1385-1393.
    View in: PubMed
    Score: 0.035
  68. Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. Clin Pharmacol Ther. 2020 09; 108(3):625-634.
    View in: PubMed
    Score: 0.034
  69. The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care. Clin Pharmacol Ther. 2019 12; 106(6):1179-1183.
    View in: PubMed
    Score: 0.032
  70. Pharmacogenetics in cancer etiology and chemotherapy. Clin Cancer Res. 1997 Jul; 3(7):1025-30.
    View in: PubMed
    Score: 0.028
  71. A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics. 2014 Feb; 24(2):129-32.
    View in: PubMed
    Score: 0.022
  72. A genome-wide integrative study of microRNAs in human liver. BMC Genomics. 2013 Jun 13; 14:395.
    View in: PubMed
    Score: 0.021
  73. Individualizing dosing of cancer chemotherapy. Semin Oncol. 1993 Feb; 20(1):30-42.
    View in: PubMed
    Score: 0.020
  74. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics. 2013 Jan; 23(1):29-33.
    View in: PubMed
    Score: 0.020
  75. Vascular endothelial growth factor pathway. Pharmacogenet Genomics. 2010 May; 20(5):346-9.
    View in: PubMed
    Score: 0.017
  76. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther. 2005 Dec; 78(6):559-81.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.